Abstract
The success of surgery to remove primary tumors can be compromised by the subsequent outgrowth of metastases. It is recognized that primary tumors secrete antiangiogenic factors that suppress the outgrowth of their daughter metastases. In accord we show here that surgical removal of primary EL-4 lymphomas led to a marked decrease in the levels of circulating angiostatin and endostatin, and promoted the growth of distant nodular tumors. Expression vectors encoding angiostatin and endostatin, formulated with poly-N-vinyl pyrrolidone (PVP), were injected into the tibialis and gastrocnemia muscles, leading to expression of angiostatin and endostatin in muscle fibers. High levels of biologically active exogenous proteins were secreted into the circulation. Intramuscular gene therapy with angiostatin and endostatin plasmids significantly inhibited tumor vascularity and induced tumor cell apoptosis, and thereby suppressed the growth of secondary subcutaneous and disseminated metastatic tumors in the lung and liver. Simultaneous intramuscular delivery of both angiostatin and endostatin plasmids significantly prolonged the survival of mice after removal of primary tumors. These results suggest that intramuscular gene transfer of angiostatin and endostatin might serve as a prophylactic cancer-prevention strategy to combat the recurrence of cancer after surgical resection of primary tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weinstat-Saslow D, Steeg PS . Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J. 1994; 8: 401–407.
Fidler IJ, Ellis LM . The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994; 79: 185–188.
O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79: 315–328.
O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88: 277–285.
Holmgren L, O'Reilly MS, Folkman J . Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995; 1: 149–153.
O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996; 2: 689–692.
Dhanabal M, Ramchandran R, Volk R, et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 1999; 59: 189–197.
Blezinger P, Wang J, Gondo M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 1999; 17: 343–348.
Cichon T, Jamrozy L, Glogowska J, et al. Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: Inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther. 2002; 9: 771–777.
Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA. 1999; 96: 2811–2816.
Kirsch M, Strasser J, Allender R, et al. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 1998; 58: 4654–4659.
Joe YA, Hong YK, Chung DS, et al. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer. 1999; 82: 694–699.
Clasesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA. 1998; 95: 5579–5583.
Redlitz A, Daum G, Sage EH . Angiostatin diminishes activation of the mitogen-activated protein kinase ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vasc Res. 1999; 36: 28–34.
Sun X, Kanwar JR, Leung E, et al. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther. 2001; 8: 719–727.
Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 2002; 519: 147–152.
Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002; 277: 27872–27879.
Hanai J, Gloy J, Karumanchi SA, et al. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol. 2002; 158: 529–539.
Furumatsu T, Yamaguchi N, Nishida K, et al. Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth. J Biochem. 2002; 131: 619–626.
Dixelius J, Cross M, Matsumoto T, et al. Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res. 2002; 62: 1944–1947.
Scappaticci FA, Smith R, Pathak A, et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther. 2001; 3: 186–196.
Scappaticci FA, Contreras A, Smith R, et al. Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis. 2001; 4: 263–268.
Putney SD, Burke PA . Improving protein therapeutics with sustained-release formulations. Nat Biotechnol. 1998; 16: 153–157.
Crystal RG . The body as a manufacturer of endostatin. Nat Biotechnol. 1999; 17: 336–337.
Boehm T, Folkman J, Browder T . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390: 404–407.
Folkman J . Antiangiogenic gene therapy. Proc Natl Acad Sci USA. 1998; 95: 9064–9066.
Kong HL, Crystal RG . Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst. 1998; 90: 273–286.
Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse skeletal muscle in vivo. Science. 1990; 247: 1465–1468.
Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res. 2004; 64: 1781–1787.
Lu QL, Bou-Gharios G, Partridge TA . Non-viral gene delivery in skeletal muscle: a protein factory. Gene Therapy. 2003; 10: 131–142.
Zabner J, Ramsey BW, Meeker DP . Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest. 1996; 97: 1504–1511.
Fisher KJ, Choi H, Burda J . Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 1996; 217: 11–22.
Yei S, Mittereder N, Tang K . Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Therapy. 1994; 1: 192–200.
McMahon JM, Wells KE, Bamfo JE, et al. Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Therapy. 1998; 5: 1283–1290.
Caron NJ, Torrente Y, Camirand G, et al. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol Ther. 2001; 3: 310–318.
Anwer K, Earle KA, Shi M, et al. Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm Res. 1999; 16: 889–895.
Fewell JG, MacLaughlin F, Mehta V, et al. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther. 2001; 3: 574–583.
Oga M, Takenaga K, Sato Y, et al. Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene. Int J Oncol. 2003; 23: 73–79.
Mumper RJ, Wang J, Klakamp SL, et al. Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle. J Control Release. 1998; 52: 191–203.
Sun X, Kanwar JR, Leung E, et al. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy. 2001; 8: 638–645.
Kanwar JR, Berg RW, Yang Y, et al. Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer Gene Ther. 2003; 10: 468–476.
Sckell A, Safabakhsh N, Dellian M, et al. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. Cancer Res. 1998; 58: 5866–5869.
Guba M, Cernaianu G, Koehl G, et al. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res. 2001; 61: 5575–5579.
Kanwar JR, Shen WP, Berg R, et al. Effect of survivin antagonists on the growth of established tumors and B7.1 immunogene therapy. J Natl Cancer Inst. 2001; 93: 1541–1552.
Maeda H, Shiraishi A . TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol. 1996; 156: 73–78.
Won J, Kim H, Park EJ, et al. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res. 1999; 59: 1273–1277.
Kanwar JR, Berg R, Lehnert K, et al. Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumour immunity. Gene Therapy. 1999; 6: 1835–1844.
Pawliuk R, Bachelot T, Zurkiya O, et al. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol Ther. 2002; 5: 345–351.
Eisterer W, Jiang X, Bachelot T, et al. Unfulfilled promise of endostatin in a gene therapy–xenotransplant model of human acute lymphocytic leukemia. Mol Ther. 2002; 5: 352–359.
Hori K, Li HC, Saito S, et al. Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470. Br J Cancer. 1997; 75: 1730–1734.
Dixelius J, Cross MJ, Matsumoto T . Endostatin action and intracellular signaling: beta-catenin as a potential target? Cancer Lett. 2003; 196: 1–12.
Lucas R, Holmgren L, Garcia I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood. 1998; 92: 4730–4741.
Wickstrom SA, Veikkola T, Rehn M . Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res. 2002; 61: 6511–6516.
Rak JW, St Croix BD, Kerbel RS . Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs. 1995; 6: 3–18.
Dixelius J, Larsson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood. 2000; 95: 3403–3411.
Oehler MK, Bicknell R . The promise of anti-angiogenic cancer therapy. Br J Cancer. 2000; 82: 749–752.
Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001; 61: 2207–2211.
Wen W, Moses MA, Wiederschain D, et al. The generation of endostatin is mediated by elastase. Cancer Res. 1999; 59: 6052–6056.
Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000; 19: 1187–1194.
O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J . Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999; 285: 1926–1928.
Kisker O, Onizuka S, Banyard J, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001; 61: 7298–7304.
Feldman AL, Libutti SK . Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 1999; 59: 3308–3312.
Acknowledgements
This work is supported in part by grants from the National Natural Scientific Foundation of China (30100178), the Scientific and Technological Committee of Shandong Province (1997BB1CJB1), a Young and Middle-aged Excellent Scientists Prize Fund from Shandong Province, China (9836), the Wellcome Trust (UK), the Maurice and Phyllis Paykel Trust, and the Health Research Council of New Zealand. X Sun is a recipient of a Wellcome Trust Research Leave Fellowship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sun, X., Qiao, H., Jiang, H. et al. Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther 12, 35–45 (2005). https://doi.org/10.1038/sj.cgt.7700766
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700766
Keywords
This article is cited by
-
Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies
Indian Journal of Surgical Oncology (2021)
-
Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice
Journal of Biomedical Science (2008)
-
A Generic Research Paradigm for Identification and Validation of Early Molecular Diagnostics and New Therapeutics in Common Disorders
Molecular Diagnosis & Therapy (2007)
-
Liposome–DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma
Cancer Gene Therapy (2006)